Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Ter Arkh ; 94(8): 979-984, 2022 Oct 12.
Artículo en Ruso | MEDLINE | ID: mdl-36286978

RESUMEN

AIM: Our aim was to give a comparative assessment of the effectiveness of using narlaprevir in combination with pegylated interferon-alpha-2a (Peg-IFN-alpha-2a) and interferon-free mode in patients with chronic hepatitis C (CHC). MATERIALS AND METHODS: The prospective cohort study included 187 patients infected with genotype 1b of hepatitis C virus. Of these, 107 (the 1st group of patients) received narlaprevir 200 mg once a day, ritonavir 100 mg once a day, Peg-IFN-alpha-2a 180 mkg subcutaneously once a week and ribavirin at a dose depending on body weight (10001200 mg per day) for 12 weeks, and then the standart "dual" therapy (Peg-IFN-alpha-2a + ribavirin) was continued until 24 weeks. Patients of the 2nd group (n=80) received antiviral therapy in an interferon-free mode. They received narlaprevir 200 mg once daily, ritonavir 100 mg once daily, and daclatasvir 60 mg once daily for 12 weeks. RESULTS: With the use of an interferon-containing treatment regimen, a sustained virological response was achieved in 92.4% of previousle untreated patients with CH and in 66.7% patients with "unsuccessful" experience of the previous course of treatment. In 5.6% of cases, there was an early termination of treatment due to the development of adverse events. 80 (100%) patients completed the course of treatment with narlaprevir in the interferon-free mode. Sustained virological response was reached by 75 (90%) patients. CONCLUSION: Real clinical practice indicates that the use of narlaprevir in the non-interferon mode is not inferior in efficiency to the interferon-containing treatment regimen and demonstrates a more favorable safety profile.


Asunto(s)
Hepatitis C Crónica , Humanos , Antivirales/uso terapéutico , Quimioterapia Combinada , Hepacivirus/genética , Hepatitis C Crónica/genética , Interferón alfa-2/uso terapéutico , Interferón-alfa/uso terapéutico , Polietilenglicoles/efectos adversos , Estudios Prospectivos , Proteínas Recombinantes/efectos adversos , Ribavirina/efectos adversos , Ritonavir/uso terapéutico , Resultado del Tratamiento
5.
Artículo en Ruso | MEDLINE | ID: mdl-1303101

RESUMEN

Native poison of middleasia viper Vipera lebetina has been included into liposomes in order to get an effective preparation for immunotherapy. The preparation reduces the risk of complications taking place during the use of traditional methods. The immunomodulating action of the liposomal form of viper poison has been investigated on the model of reaction of hypersensitivity of delayed type. Together with the stimulation of functional activity T-cells, the absence of suppressive and toxic actions while using the liposomal preparation of poison has been discovered. It is suggested that the observed stimulating effect in connection with immune reactions is due to synergism of action of components of poison liposomal form and activation of T-cells and macrophage, taking part in immune response to the antigenic stimulus.


Asunto(s)
Hipersensibilidad Tardía/etiología , Venenos de Víboras/farmacología , Animales , Portadores de Fármacos , Hipersensibilidad Tardía/inmunología , Inmunidad Celular/efectos de los fármacos , Inmunización , Liposomas , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Endogámicos CBA , Estimulación Química
6.
Patol Fiziol Eksp Ter ; (4): 22-4, 1991.
Artículo en Ruso | MEDLINE | ID: mdl-1798644

RESUMEN

The effect of bee venom (0.05 and 0.5 mg/kg) and the venom of Vipera lebetina (0.05 and 0.5 mg/kg) on the reaction of delayed hypersensitivity was studied in experiments on CBA mice. The character and trend of the effect was determined by the zootoxin species. The venom of Vipera lebetina completely suppressed the cell immune reaction in a dose of 0.5 mg/kg and produced an adjuvant effect in a dose of 0.05 mg/kg. Bee venom (0.5 mg/kg) failed to cause a suppressive effect and in a small dose (0.05 mg/kg) stimulated cellular immunity. The adjuvant properties of the venoms were comparable with the effect of Evans' blue dye.


Asunto(s)
Hipersensibilidad a las Drogas/inmunología , Hipersensibilidad Tardía/inducido químicamente , Toxinas Biológicas/farmacología , Animales , Venenos de Abeja/farmacología , Relación Dosis-Respuesta a Droga , Femenino , Hipersensibilidad Tardía/inmunología , Inmunidad Celular/efectos de los fármacos , Inmunidad Celular/inmunología , Inmunización/métodos , Ratones , Ratones Endogámicos CBA , Venenos de Víboras/farmacología
7.
Ter Arkh ; 63(8): 108-10, 1991.
Artículo en Ruso | MEDLINE | ID: mdl-1792596

RESUMEN

Overall 46 patients with allergic reactions to bee stings were examined. As a result of making skin prick, scarification and intracutaneous tests with an allergen from bee venom, allergy to bee stings was revealed in all the 46 patients, whereas only 37 patients responded to an allergen from the bee body. Specific IgE-antibodies using RAST were detected in 29 out of 31 patients. All the 29 patients had positive skin tests with an allergen from bee venom and only 22 with an allergen from the bee body. Specific histamine release was detected in all 13 patients examined by means of the indicated test. 100% coincidence was recorded with the results of intracutaneous tests with an allergen from bee venom. Only 11 out of the 13 patients had positive intracutaneous tests with an allergen from the bee body. Thus, the new Soviet allergen obtained from bee venom is effective in the diagnosis of allergy in response to bee stings.


Asunto(s)
Alérgenos , Venenos de Abeja , Abejas , Hipersensibilidad/diagnóstico , Mordeduras y Picaduras de Insectos/diagnóstico , Adolescente , Adulto , Alérgenos/aislamiento & purificación , Animales , Abejas/inmunología , Niño , Evaluación de Medicamentos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Pruebas Cutáneas
8.
Lab Delo ; (3): 55-7, 1989.
Artículo en Ruso | MEDLINE | ID: mdl-2469844

RESUMEN

Haptoglobin (Hp) phenotype distribution has been examined in 193 patients with an acute icteric form of hepatitis B (HBsAg+), in 36 chronic HBsAg carriers, and in 317 normal controls. The incidence rates of three Hp types have been virtually the same in the acute patients and in the controls. In chronic HBsAg carriers the Hp 1-1 type has been detected 3 times more frequently than in acute hepatitis B patients and 4 times more frequently than in normal subjects. The authors suppose that the presence of Hp 1-1 type is one of the genetic factors that determine (in case of a hepatitis B infection) the liability to the development of a chronic subclinical infectious process and not of an acute form of this infection.


Asunto(s)
Portador Sano/inmunología , Haptoglobinas/genética , Antígenos de Superficie de la Hepatitis B/análisis , Hepatitis B/genética , Electroforesis de las Proteínas Sanguíneas , Humanos , Fenotipo
9.
Artículo en Ruso | MEDLINE | ID: mdl-3593804

RESUMEN

The rheological properties of blood (viscosity, suspension stability and deformation of red blood cells) have been studied under the influence of zootoxins. It has been shown that the toxins Apis mellifera, Mesobuthus eupeus, Agkistrodon blomhoffii in vitro exert essential effect on haemorheological indexes.


Asunto(s)
Viscosidad Sanguínea/efectos de los fármacos , Deformación Eritrocítica/efectos de los fármacos , Ponzoñas/farmacología , Animales , Técnicas In Vitro , Meliteno/farmacología , Ratas , Reología , Venenos de Escorpión/farmacología , Venenos de Serpiente/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...